Mucosal  ||| S:0 E:8 ||| JJ
immunity  ||| S:8 E:17 ||| NN
and  ||| S:17 E:21 ||| CC
sublingual  ||| S:21 E:32 ||| JJ
immunotherapy  ||| S:32 E:46 ||| NN
in  ||| S:46 E:49 ||| IN
respiratory  ||| S:49 E:61 ||| JJ
disorders  ||| S:61 E:71 ||| NNS
The  ||| S:71 E:75 ||| DT
increasing  ||| S:75 E:86 ||| JJ
prevalence  ||| S:86 E:97 ||| NN
of  ||| S:97 E:100 ||| IN
allergy  ||| S:100 E:108 ||| NN
and  ||| S:108 E:112 ||| CC
its  ||| S:112 E:116 ||| PRP$
impact  ||| S:116 E:123 ||| NN
on  ||| S:123 E:126 ||| IN
individual  ||| S:126 E:137 ||| JJ
quality  ||| S:137 E:145 ||| NN
of  ||| S:145 E:148 ||| IN
life  ||| S:148 E:153 ||| NN
underline  ||| S:153 E:163 ||| VBD
the  ||| S:163 E:167 ||| DT
need  ||| S:167 E:172 ||| NN
of  ||| S:172 E:175 ||| IN
an  ||| S:175 E:178 ||| DT
improvement  ||| S:178 E:190 ||| NN
of  ||| S:190 E:193 ||| IN
the  ||| S:193 E:197 ||| DT
treatment  ||| S:197 E:207 ||| NN
options  ||| S:207 E:215 ||| NNS
in  ||| S:215 E:218 ||| IN
order  ||| S:218 E:224 ||| NN
to  ||| S:224 E:227 ||| TO
modify  ||| S:227 E:234 ||| VB
the  ||| S:234 E:238 ||| DT
natural  ||| S:238 E:246 ||| JJ
course  ||| S:246 E:253 ||| NN
of  ||| S:253 E:256 ||| IN
allergic  ||| S:256 E:265 ||| JJ
diseases ||| S:265 E:273 ||| NNS
.  ||| S:273 E:275 ||| .
In  ||| S:275 E:278 ||| IN
this  ||| S:278 E:283 ||| DT
context ||| S:283 E:290 ||| NN
,  ||| S:290 E:292 ||| ,
specific  ||| S:292 E:301 ||| JJ
sublingual  ||| S:301 E:312 ||| JJ
immunotherapy  ||| S:312 E:326 ||| NNS
( ||| S:326 E:327 ||| -LRB-
SLIT ||| S:327 E:331 ||| NNP
)  ||| S:331 E:333 ||| -RRB-
represents  ||| S:333 E:344 ||| VBZ
an  ||| S:344 E:347 ||| DT
approach  ||| S:347 E:356 ||| NN
currently  ||| S:356 E:366 ||| RB
available  ||| S:366 E:376 ||| JJ
to  ||| S:376 E:379 ||| TO
redirect  ||| S:379 E:388 ||| VB
inappropriate  ||| S:388 E:402 ||| JJ
immune  ||| S:402 E:409 ||| JJ
response  ||| S:409 E:418 ||| NN
in  ||| S:418 E:421 ||| IN
atopic  ||| S:421 E:428 ||| JJ
patients ||| S:428 E:436 ||| NNS
.  ||| S:436 E:438 ||| .
The  ||| S:438 E:442 ||| DT
immunological  ||| S:442 E:456 ||| JJ
mechanism  ||| S:456 E:466 ||| NN
that  ||| S:466 E:471 ||| IN
underlies  ||| S:471 E:481 ||| JJ
SLIT  ||| S:481 E:486 ||| NNP
has  ||| S:486 E:490 ||| VBZ
only  ||| S:490 E:495 ||| RB
started  ||| S:495 E:503 ||| VBN
to  ||| S:503 E:506 ||| TO
be  ||| S:506 E:509 ||| VB
investigated ||| S:509 E:521 ||| VBN
.  ||| S:521 E:523 ||| .
Oral  ||| S:523 E:528 ||| JJ
mucosal  ||| S:528 E:536 ||| JJ
tissue  ||| S:536 E:543 ||| NN
displays  ||| S:543 E:552 ||| NNS
high  ||| S:552 E:557 ||| JJ
permeability  ||| S:557 E:570 ||| NN
for  ||| S:570 E:574 ||| IN
allergens ||| S:574 E:583 ||| NN
.  ||| S:583 E:585 ||| .
It  ||| S:585 E:588 ||| PRP
is  ||| S:588 E:591 ||| VBZ
conceivable  ||| S:591 E:603 ||| VBN
that  ||| S:603 E:608 ||| IN
the  ||| S:608 E:612 ||| DT
sublingual  ||| S:612 E:623 ||| JJ
administration  ||| S:623 E:638 ||| NN
route  ||| S:638 E:644 ||| NN
might  ||| S:644 E:650 ||| MD
induce  ||| S:650 E:657 ||| VB
immunological  ||| S:657 E:671 ||| JJ
tolerance  ||| S:671 E:681 ||| NN
towards  ||| S:681 E:689 ||| IN
allergens  ||| S:689 E:699 ||| NNS
involving  ||| S:699 E:709 ||| VBG
cells  ||| S:709 E:715 ||| NNS
and  ||| S:715 E:719 ||| CC
mediators  ||| S:719 E:729 ||| JJ
specific  ||| S:729 E:738 ||| JJ
of  ||| S:738 E:741 ||| IN
oral  ||| S:741 E:746 ||| JJ
and  ||| S:746 E:750 ||| CC
intestinal  ||| S:750 E:761 ||| JJ
mucosa ||| S:761 E:767 ||| NN
.  ||| S:767 E:769 ||| .
Recent  ||| S:769 E:776 ||| JJ
literature  ||| S:776 E:787 ||| NN
data  ||| S:787 E:792 ||| NNS
stated  ||| S:792 E:799 ||| VBD
the  ||| S:799 E:803 ||| DT
presence  ||| S:803 E:812 ||| NN
in  ||| S:812 E:815 ||| IN
oral  ||| S:815 E:820 ||| JJ
mucosa  ||| S:820 E:827 ||| NN
of  ||| S:827 E:830 ||| IN
dendritic  ||| S:830 E:840 ||| JJ
cells  ||| S:840 E:846 ||| NNS
( ||| S:846 E:847 ||| -LRB-
DCs ||| S:847 E:850 ||| NNP
)  ||| S:850 E:852 ||| -RRB-
which  ||| S:852 E:858 ||| WDT
express  ||| S:858 E:866 ||| VBP
the  ||| S:866 E:870 ||| DT
high-affinity  ||| S:870 E:884 ||| JJ
receptor  ||| S:884 E:893 ||| NN
for  ||| S:893 E:897 ||| IN
immunoglobulin  ||| S:897 E:912 ||| NNS
( ||| S:912 E:913 ||| -LRB-
Ig ||| S:913 E:915 ||| NNP
) ||| S:915 E:916 ||| -RRB-
E  ||| S:916 E:918 ||| NNP
( ||| S:918 E:919 ||| -LRB-
FcERI ||| S:919 E:924 ||| NNP
) ||| S:924 E:925 ||| -RRB-
.  ||| S:925 E:927 ||| .
Moreover  ||| S:927 E:936 ||| RB
some  ||| S:936 E:941 ||| DT
studies  ||| S:941 E:949 ||| NNS
indicated  ||| S:949 E:959 ||| VBD
that  ||| S:959 E:964 ||| IN
the  ||| S:964 E:968 ||| DT
mechanism  ||| S:968 E:978 ||| NN
of  ||| S:978 E:981 ||| IN
immunotherapy  ||| S:981 E:995 ||| NNS
might  ||| S:995 E:1001 ||| MD
be  ||| S:1001 E:1004 ||| VB
based  ||| S:1004 E:1010 ||| VBN
on  ||| S:1010 E:1013 ||| IN
the  ||| S:1013 E:1017 ||| DT
increase  ||| S:1017 E:1026 ||| NN
of  ||| S:1026 E:1029 ||| IN
number  ||| S:1029 E:1036 ||| NN
and  ||| S:1036 E:1040 ||| CC
activity  ||| S:1040 E:1049 ||| NN
of  ||| S:1049 E:1052 ||| IN
regulatory  ||| S:1052 E:1063 ||| JJ
T  ||| S:1063 E:1065 ||| NN
cells ||| S:1065 E:1070 ||| NNS
.  ||| S:1070 E:1072 ||| .
Accumulating  ||| S:1072 E:1085 ||| VBG
evidences  ||| S:1085 E:1095 ||| NNS
suggest  ||| S:1095 E:1103 ||| VBP
that  ||| S:1103 E:1108 ||| IN
the  ||| S:1108 E:1112 ||| DT
generation  ||| S:1112 E:1123 ||| NN
of  ||| S:1123 E:1126 ||| IN
T  ||| S:1126 E:1128 ||| NN
regulatory  ||| S:1128 E:1139 ||| JJ
cells  ||| S:1139 E:1145 ||| NNS
in  ||| S:1145 E:1148 ||| IN
periphery  ||| S:1148 E:1158 ||| NN
is  ||| S:1158 E:1161 ||| VBZ
orchestrated  ||| S:1161 E:1174 ||| VBN
by  ||| S:1174 E:1177 ||| IN
a  ||| S:1177 E:1179 ||| DT
particular  ||| S:1179 E:1190 ||| JJ
subset  ||| S:1190 E:1197 ||| NN
of  ||| S:1197 E:1200 ||| IN
DCs ||| S:1200 E:1203 ||| JJ
.  ||| S:1203 E:1205 ||| .
It  ||| S:1205 E:1208 ||| PRP
seems  ||| S:1208 E:1214 ||| VBZ
that  ||| S:1214 E:1219 ||| DT
repeated  ||| S:1219 E:1228 ||| JJ
stimulation  ||| S:1228 E:1240 ||| NN
of  ||| S:1240 E:1243 ||| IN
naive  ||| S:1243 E:1249 ||| JJ
CD4  ||| S:1249 E:1253 ||| CD
T  ||| S:1253 E:1255 ||| NN
cells  ||| S:1255 E:1261 ||| NNS
with  ||| S:1261 E:1266 ||| IN
allogenic  ||| S:1266 E:1276 ||| FW
immature  ||| S:1276 E:1285 ||| FW
DCs  ||| S:1285 E:1289 ||| FW
induce  ||| S:1289 E:1296 ||| FW
Tr1  ||| S:1296 E:1300 ||| FW
cells  ||| S:1300 E:1306 ||| FW
maturation ||| S:1306 E:1316 ||| FW
.  ||| S:1316 E:1318 ||| .
Nevertheless  ||| S:1318 E:1331 ||| RB
other  ||| S:1331 E:1337 ||| JJ
cells  ||| S:1337 E:1343 ||| NNS
are  ||| S:1343 E:1347 ||| VBP
involved  ||| S:1347 E:1356 ||| VBN
in  ||| S:1356 E:1359 ||| IN
this  ||| S:1359 E:1364 ||| DT
process ||| S:1364 E:1371 ||| NN
,  ||| S:1371 E:1373 ||| ,
such  ||| S:1373 E:1378 ||| JJ
as  ||| S:1378 E:1381 ||| IN
TLR ||| S:1381 E:1384 ||| NNP
,  ||| S:1384 E:1386 ||| ,
MHC  ||| S:1386 E:1390 ||| NNP
of  ||| S:1390 E:1393 ||| IN
I  ||| S:1393 E:1395 ||| PRP
and  ||| S:1395 E:1399 ||| CC
II  ||| S:1399 E:1402 ||| NNP
class  ||| S:1402 E:1408 ||| NN
and  ||| S:1408 E:1412 ||| CC
costimolatory  ||| S:1412 E:1426 ||| JJ
molecules  ||| S:1426 E:1436 ||| NNS
such  ||| S:1436 E:1441 ||| JJ
as  ||| S:1441 E:1444 ||| IN
CD40 ||| S:1444 E:1448 ||| NNP
,  ||| S:1448 E:1450 ||| ,
CD  ||| S:1450 E:1453 ||| NNP
80 ||| S:1453 E:1455 ||| CD
/ ||| S:1455 E:1456 ||| CD
B7.1  ||| S:1456 E:1461 ||| CD
and  ||| S:1461 E:1465 ||| CC
CD  ||| S:1465 E:1468 ||| NNP
86 ||| S:1468 E:1470 ||| CD
/ ||| S:1470 E:1471 ||| CD
B7.2 ||| S:1471 E:1475 ||| CD
.  ||| S:1475 E:1477 ||| .
An  ||| S:1477 E:1480 ||| DT
increase  ||| S:1480 E:1489 ||| NN
of  ||| S:1489 E:1492 ||| IN
serum  ||| S:1492 E:1498 ||| JJ
IgG4  ||| S:1498 E:1503 ||| NN
and  ||| S:1503 E:1507 ||| CC
IgA ||| S:1507 E:1510 ||| JJ
,  ||| S:1510 E:1512 ||| ,
a  ||| S:1512 E:1514 ||| DT
reduced  ||| S:1514 E:1522 ||| JJ
number  ||| S:1522 E:1529 ||| NN
of  ||| S:1529 E:1532 ||| IN
inflammatory  ||| S:1532 E:1545 ||| JJ
cells  ||| S:1545 E:1551 ||| NNS
infiltrating  ||| S:1551 E:1564 ||| VBG
target  ||| S:1564 E:1571 ||| NN
organs ||| S:1571 E:1577 ||| NNS
,  ||| S:1577 E:1579 ||| ,
as  ||| S:1579 E:1582 ||| RB
well  ||| S:1582 E:1587 ||| RB
as  ||| S:1587 E:1590 ||| IN
a  ||| S:1590 E:1592 ||| DT
reduction  ||| S:1592 E:1602 ||| NN
of  ||| S:1602 E:1605 ||| IN
eosinophilic  ||| S:1605 E:1618 ||| JJ
cationic  ||| S:1618 E:1627 ||| JJ
protein  ||| S:1627 E:1635 ||| NN
and  ||| S:1635 E:1639 ||| CC
a  ||| S:1639 E:1641 ||| DT
very  ||| S:1641 E:1646 ||| RB
heterogenous  ||| S:1646 E:1659 ||| JJ
influence  ||| S:1659 E:1669 ||| NN
on  ||| S:1669 E:1672 ||| IN
T  ||| S:1672 E:1674 ||| NN
cells  ||| S:1674 E:1680 ||| NNS
in  ||| S:1680 E:1683 ||| IN
the  ||| S:1683 E:1687 ||| DT
peripheral  ||| S:1687 E:1698 ||| JJ
blood  ||| S:1698 E:1704 ||| NN
in  ||| S:1704 E:1707 ||| IN
terms  ||| S:1707 E:1713 ||| NNS
of  ||| S:1713 E:1716 ||| IN
T  ||| S:1716 E:1718 ||| NN
cell  ||| S:1718 E:1723 ||| NN
suppression  ||| S:1723 E:1735 ||| NN
also  ||| S:1735 E:1740 ||| RB
occur  ||| S:1740 E:1746 ||| VB
with  ||| S:1746 E:1751 ||| IN
SLIT ||| S:1751 E:1755 ||| NNP
.  ||| S:1755 E:1757 ||| .
All  ||| S:1757 E:1761 ||| PDT
these  ||| S:1761 E:1767 ||| DT
molecules  ||| S:1767 E:1777 ||| NNS
orchestrate  ||| S:1777 E:1789 ||| VBP
the  ||| S:1789 E:1793 ||| DT
immune  ||| S:1793 E:1800 ||| JJ
response  ||| S:1800 E:1809 ||| NN
within  ||| S:1809 E:1816 ||| IN
the  ||| S:1816 E:1820 ||| DT
regional  ||| S:1820 E:1829 ||| JJ
immune  ||| S:1829 E:1836 ||| JJ
system ||| S:1836 E:1842 ||| NN
,  ||| S:1842 E:1844 ||| ,
recreating  ||| S:1844 E:1855 ||| VBG
a  ||| S:1855 E:1857 ||| DT
favourite  ||| S:1857 E:1867 ||| JJ
environment  ||| S:1867 E:1879 ||| NN
for  ||| S:1879 E:1883 ||| IN
the  ||| S:1883 E:1887 ||| DT
induction  ||| S:1887 E:1897 ||| NN
of  ||| S:1897 E:1900 ||| IN
tolerance  ||| S:1900 E:1910 ||| NN
operated  ||| S:1910 E:1919 ||| VBD
by  ||| S:1919 E:1922 ||| IN
SLIT ||| S:1922 E:1926 ||| NNP
.  ||| S:1926 E:1928 ||| .
